Comprehensive insertion-site analysis showed vector integration that targeted multiple genes controlling growth and immunologic responses in a persistently polyclonal hematopoiesis.”
mosaic virus (TMV) derivatives are explored currently extensively with regard to nanotechnological applications. Since certain technically desired TMV mutants may not be accessible from plants, the utility of the fission yeast Schizosaccharomyces pombe for heterologous production of TMV coat protein (CP) variants was explored, including wild-type (wt) CP and two genetically engineered mutants: TMV-CP-His(6) containing a C-terminal hexahistidine (Hiss) tag, and TMV-CP-E50Q with enhanced lateral CP subunit interactions. After establishing expression clones and protocols for enrichment of the CP variants, their ability to reconstitute TMV-like nanostructures in the presence or absence of RNA was tested in comparison with the corresponding Tariquidar plant-derived CP variants, which were expressed from infectious TMV constructs. Both TMV-CP-E50Q and TMV-CP-wt yielded TMV-like rods, irrespective of the proteins’ source. In contrast, His-tagged CP from plants produced only Blasticidin S molecular weight short rods in an inefficient manner, and no rods at all when expressed in yeast. This study introduces
a novel approach to produce assembly competent TMV CP, but also demonstrates its limitations. (C) 2010 Elsevier B.V. All rights reserved.”
“Background: Adverse events in patients who have Org 27569 undergone surgery constitute a large proportion of iatrogenic illnesses. Most surgical safety interventions have focused on the operating room. Since more than half of all surgical errors occur outside the operating room, it is likely that a more substantial improvement in outcomes can be achieved by targeting the entire surgical pathway.
Methods: We examined the effects on patient outcomes of a comprehensive, multidisciplinary surgical safety checklist, including items such as medication, marking of the operative side, and use of postoperative instructions. The checklist was implemented
in six hospitals with high standards of care. All complications occurring during admission were documented prospectively. We compared the rate of complications during a baseline period of 3 months with the rate during a 3-month period after implementation of the checklist, while accounting for potential confounders. Similar data were collected from a control group of five hospitals.
Results: In a comparison of 3760 patients observed before implementation of the checklist with 3820 patients observed after implementation, the total number of complications per 100 patients decreased from 27.3 (95% confidence interval [CI], 25.9 to 28.7) to 16.7 (95% CI, 15.6 to 17.9), for an absolute risk reduction of 10.6 (95% CI, 8.7 to 12.4). The proportion of patients with one or more complications decreased from 15.4% to 10.6% (P<0.001). In-hospital mortality decreased from 1.5% (95% CI, 1.2 to 2.0) to 0.